Neurocrine Biosciences Inc.'s investors were revved up Wednesday on the news that the firm had inked an exclusive worldwide deal potentially worth more than $575 million, including $75 million up front, with Abbott to develop and commercialize elagolix, a first-in-class oral gonadotropin-releasing hormone antagonist (GnRH), for the treatment of endometriosis-related pain. (BioWorld Today)